SYSTEMATIC LITERATURE REVIEW FOR TREATMENT OUTCOMES (INCLUDING IMMUNO-ONCOLOGY TREATMENT) AMONG PATIENTS WITH STAGE 3 UNRESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC)

被引：1
|
作者：
Zhou, Z. [1 ]
Song, J. [2 ]
Ouwens, M. J. [3 ]
Huhn, M. [3 ]
Jiang, H. [4 ]
Zhang, Y. [4 ]
Dalevi, D. [3 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Anal Grp Inc, Los Angeles, CA USA
[3] Astrazeneca, Molndal, Sweden
[4] Astrazeneca, Gaithersburg, MD USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.110
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN28
引用
收藏
页码：A416 / A416
页数：1
相关论文
共 50 条
  • [21] Treatment outcome of patients with unresectable stage III non-small cell lung cancer and interstitial pneumonia
    Ogawa, Kazumasa
    Takahashi, Yui
    Murase, Kyoko
    Hanada, Shigeo
    Uruga, Hironori
    Takaya, Hisashi
    Miyamoto, Atsushi
    Morokawa, Nasa
    Kurosaki, Atsuko
    Kishi, Kazuma
    [J]. RESPIRATORY INVESTIGATION, 2019, 57 (04) : 388 - 394
  • [22] A REVIEW ON CURRENT TREATMENT OPTIONS AND EVOLUTION OF TREATMENT STRATEGIES FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Vesangikeerthivaishnavi
    Tekulashivasai
    Doranalaharshini
    Sreenivaspasulai
    [J]. INTERNATIONAL JOURNAL OF LIFE SCIENCE AND PHARMA RESEARCH, 2020, : 220 - 223
  • [23] THE IMPACT OF RESPONSE AT A LANDMARK ON OVERALL SURVIVAL: IMPLICATIONS FOR THE ECONOMIC EVALUATION OF THE VALUE OF IMMUNO-ONCOLOGY (I-O) TREATMENT IN NON-SMALL CELL LUNG CANCER (NSCLC)
    Santi, I
    Johal, S.
    Yuan, Y.
    Penrod, J. R.
    [J]. VALUE IN HEALTH, 2018, 21 : S211 - S211
  • [24] Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC)
    Gijtenbeek, Rolof G. P.
    Helfrich, Gea
    Venmans, Ben J. W.
    Ten Brinke, Anneke
    De Jong, Kim
    Van Geffen, Wouter H.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [25] The cost of non-small cell lung cancer (NSCLC) treatment
    Vergnenegre, A.
    [J]. ONCOLOGIE, 2012, 14 (05) : 310 - 315
  • [26] 3 years of experience in stereotactic treatment of stage I Non-Small Cell Lung Cancer (NSCLC)
    Meijburg, M.
    Van Gurp, C.
    Slotman, B.
    Cuijpers, J.
    Lagerwaard, F.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2007, 84 : S36 - S36
  • [27] CURATIVE TREATMENT OF STAGE I NON-SMALL CELL LUNG CANCER IN PATIENTS WITH SEVERE COPD: STEREOTACTIC RADIOTHERAPY OUTCOMES AND SYSTEMATIC REVIEW
    Palma, David
    Lagerwaard, Frank J.
    Rodrigues, George
    Haasbeek, Cornelis J.
    Senan, Suresh
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S384 - S385
  • [28] Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK1) non-small cell lung cancer (NSCLC) in the United States
    Pan, X.
    Lin, M. M.
    Yin, Y.
    Hou, P.
    Baumann, P.
    Jahanzeb, M.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [29] Metastatic Non-Small Cell Lung Cancer With EGFR Mutations: Treatment Pattern and Outcomes From a Systematic Literature Review
    Gadgeel, S.
    Wang, E.
    Phani, S.
    Wu, C.
    Salas, M.
    Meng, J.
    Diamand, F.
    Esker, S.
    Lim, D. W. -T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S667 - S667
  • [30] Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review
    Garon, Edward B.
    Visseren-Grul, Carla
    Rizzo, Maria Teresa
    Puri, Tarun
    Chenji, Suresh
    Reck, Martin
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
12345